Drug Profile
SHX 009
Alternative Names: SHX-009Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Shenox Pharmaceuticals
- Class Behavioural disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Attention-deficit-hyperactivity-disorder(In children) in USA (Transdermal, Patch)
- 08 Nov 2018 Early research in Attention-deficit hyperactivity disorder (In children) in USA (Transdermal) (Shenox Pharmaceuticals pipeline, November 2018)